Medcorp Limited (TTSE:MED)
Trinidad and Tobago flag Trinidad and Tobago · Delayed Price · Currency is TTD
44.00
0.00 (0.00%)
At close: Apr 8, 2026

Medcorp Cash Flow Statement

Millions TTD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Net Income
18.1841.3157.0724.1324.49
Depreciation & Amortization
16.216.5810.998.164.94
Loss (Gain) From Sale of Assets
--0-0.12-
Asset Writedown & Restructuring Costs
---0--
Loss (Gain) on Equity Investments
-2.45-4.83-4.98-1.72-1.99
Provision & Write-off of Bad Debts
1.27-1.40.771.060.87
Other Operating Activities
3.33-26.189.960.273.69
Change in Accounts Receivable
-1.244.31-17.148.39-7.89
Change in Inventory
-1.24-0.830.44-0.12-0.96
Change in Accounts Payable
-2.72.680.967.7-1.82
Change in Other Net Operating Assets
-6.84-6.92-23.77-3.83-0.29
Operating Cash Flow
24.5224.7334.3143.9121.04
Operating Cash Flow Growth
-0.83%-27.92%-21.87%108.66%-12.55%
Capital Expenditures
-1.76-4.6-5.6-18.5-15.38
Sale of Property, Plant & Equipment
-0.03-0.52-
Investment in Securities
-13--0.687.91
Other Investing Activities
--4.54.652.3
Investing Cash Flow
-14.76-4.57-1.1-12.64-5.17
Long-Term Debt Issued
---4.535.69
Long-Term Debt Repaid
-15.9-19.89-16.64-7.49-7.49
Net Debt Issued (Repaid)
-15.9-19.89-16.64-2.96-1.8
Issuance of Common Stock
14.7----
Common Dividends Paid
-7.83-18.7-7.48-28.89-11.22
Other Financing Activities
-0.09-1-0.61-0.9-0.44
Financing Cash Flow
-9.13-39.59-24.73-32.75-13.46
Net Cash Flow
0.63-19.448.48-1.492.41
Free Cash Flow
22.7620.1228.7125.415.66
Free Cash Flow Growth
13.11%-29.89%12.96%349.02%-71.38%
Free Cash Flow Margin
18.70%16.46%22.60%20.79%4.96%
Free Cash Flow Per Share
2.972.693.843.400.76
Cash Interest Paid
-10.610.90.44
Cash Income Tax Paid
-13.068.068.958.78
Levered Free Cash Flow
14.5722.89-7.1616.420.1
Unlevered Free Cash Flow
17.2826.61-5.1617.951.54
Change in Working Capital
-12.02-0.75-39.512.14-10.95
Source: S&P Global Market Intelligence. Standard template. Financial Sources.